ArticleRheumatology (Oxford, England)2020
Interleukin-36 family dysregulation drives joint inflammation and therapy response in psoriatic arthritis.
Article in Rheumatology (Oxford, England), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 55 citations in OpenAlex.
- Clinical Practice Recommendations for Non-Dermatologists on the Diagnostic Suspicion of GPP.Journal of clinical medicine · 2026Review
- Advances in targeting IL-1 family cytokines for the treatment of inflammatory diseases.Nature reviews. Rheumatology · 2026Review
- Aged skin exacerbates experimental osteoarthritis via enhanced IL-36R signaling.Nature communications · 2026Article
- The IL-36 Cytokine Rheostat: Hierarchical Regulation of Epithelial-Immune Crosstalk and Precision Therapy in Psoriatic and Related Dermatoses.Clinical, cosmetic and investigational dermatology · 2026Review
- Sex differences in serum proteomic profiles in psoriatic arthritis.Rheumatology (Oxford, England) · 2025Article
- Synovial MS4A4A correlates with inflammation and counteracts response to corticosteroids in arthritis.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Skin and Nail Predictors of Psoriatic Arthritis Development: A Holistic Overview Integrating Epidemiological and Physiopathological Data.Journal of clinical medicine · 2024Review
- Molecular maps of synovial cells in inflammatory arthritis using an optimized synovial tissue dissociation protocol.iScience · 2024Article
- Generalized Pustular Psoriasis and Systemic Organ Dysfunctions.International journal of molecular sciences · 2024Review
- Signaling pathways and targeted therapies for psoriasis.Signal transduction and targeted therapy · 2023Review
- IL-36γ Augments Ocular Angiogenesis by Promoting the Vascular Endothelial Growth Factor-Vascular Endothelial Growth Factor Receptor Axis.The American journal of pathology · 2023Article
- Consideration of serum IL-36α and β levels trends in two patients with chikungunya fever.Clinical case reports · 2023Article
- Discovery of CLEC2B as a diagnostic biomarker and screening of celastrol as a candidate drug for psoriatic arthritis through bioinformatics analysis.Journal of orthopaedic surgery and research · 2023Article
- Serum Interleukin-36 α as a Candidate Biomarker to Distinguish Behçet's Syndrome and Psoriatic Arthritis.International journal of molecular sciences · 2023Article
- Cutaneous lesions in psoriatic arthritis are enriched in chemokine transcriptomic pathways.Arthritis research & therapy · 2023Article
- Role of Interleukin-36 in inflammatory joint diseases.Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences · 2023Review
- The role of the interleukin-36 axis in generalized pustular psoriasis: a review of the mechanism of action of spesolimab.Frontiers in immunology · 2023Review
- IL-36γ in enthesitis-related juvenile idiopathic arthritis and its association with disease activity.Clinical and experimental immunology · 2022Article
- Histopathology of Psoriatic Arthritis Synovium-A Narrative Review.Frontiers in medicine · 2022Review
- Pathophysiology of Generalized Pustular Psoriasis.American journal of clinical dermatology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
Abstract
objectivesIL-36 agonists are pro-inflammatory cytokines involved in the pathogenesis of psoriasis. However, their role in the pathogenesis of arthritis and treatment response to DMARDs in PsA remains uncertain. Therefore, we investigated the IL-36 axis in the synovium of early, treatment-naïve PsA, and for comparison RA patients, pre- and post-DMARDs therapy.
methodsSynovial tissues were collected by US-guided biopsy from patients with early, treatment-naïve PsA and RA at baseline and 6 months after DMARDs therapy. IL-36 family members were investigated in synovium by RNA sequencing and immunohistochemistry, and expression levels correlated with DMARDs treatment response ex vivo. Additionally, DMARDs effects on IL-36 were investigated in vitro in fibroblast-like synoviocytes.
resultsPsA synovium displayed a reduced expression of IL-36 antagonists, while IL-36 agonists were comparable between PsA and RA. Additionally, neutrophil-related molecules, which drive a higher activation of the IL-36 pathway, were upregulated in PsA compared with RA. At baseline, the synovial expression of IL-36α was significantly higher in PsA non-responders to DMARDs treatment, with the differential expression being sustained at 6 months post-treatment. In vitro, primary PsA-derived fibroblasts were more responsive to IL-36 stimulation compared with RA and, importantly, DMARDs treatment increased IL-36 expression in PsA fibroblasts.
conclusionThe impaired balance between IL-36 agonists-antagonists described herein for the first time in PsA synovium and the decreased sensitivity to DMARDs in vitro may explain the apparent lower efficacy of DMARDs in PsA compared with RA. Exogenous replacement of IL-36 antagonists may be a novel promising therapeutic target for PsA patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.